Skip to Late-Breaking Abstracts »
All odd numbered posters will be presented on Friday, November 8, 2019, while even numbered posters will be presented on Saturday, November 9, 2019.
Posters will be on display from 7 a.m. - 8 p.m., with the presenting authors required to be at their posters during lunch (12:30 - 2 p.m. on Friday, Nov. 8, and 12:35 - 2:05 p.m. on Saturday, Nov. 9) and also during the poster reception (6:30 - 8p.m. on Friday, Nov. 8, and 7 - 8:30 p.m. on Saturday, Nov. 9).
# | Title | Authors | Category | Keywords |
---|---|---|---|---|
O4 | Preclinical CAR-T cell target safety, biodistribution, and tumor infiltration analysis using in situ hybridization technology | Courtney M. Anderson, PhD; Helly Xiao Yan Pimentel; Helen Jarnagin; Hailing Zong; Courtney Todorov; Kenneth Ganley; Fay Eng; Kevin Friedman, PhD; Molly R. Perkins; Shannon Grande, PhD; Bingqing Zhang; Christopher Bunker; Xiao-Jun Ma; James R. Rottman; Courtney M. Anderson, PhD; | Cellular Therapies | CAR T cells; Cytokine; Gene expression; Solid tumors; T cell; Targeted therapy; Tumor antigens; Tumor microenvironment |
O5 | The road-map to Tumor-Infiltrating Lymphocyte (TIL) therapy: Understanding genetic alterations for improved patient treatment | Caitlin Creasy, MS; Yuzhong J. Meng, PhD; Tatiana Karpinets, MS; Cara Haymaker, PhD; Marie Andrée Forget, PhD; Chip Stewart, PhD; Carlos Antonio Torres Cabala, MD; Shari A. Pilon-Thomas, PhD; Amod A. Sarnaik, MD; Levi A. Garraway, MD, PhD; Patrick Hwu, MD; Rodabe N. Amaria, MD; Rameen Beroukhim, M.D, PhD; Chantale Bernatchez; | Cellular Therapies | Adoptive immunotherapy; Clinical trial; Gene expression; Immune contexture; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
O6 | Enhanced presence of a myeloid-like NK cell subpopulation is associated with MHC class I-deficient tumor escape | Yimin Du, PhD; Curtis J. Perry, MD/PhD; William Damsky, MD, PhD; Katherine Hastings, PhD; Patricia Rodriguez-Morales; Dan Chen, PhD; Kacie Traina; Ivy Phung; Ting Zhou; Aaron M. Ring, MD, PhD; Katerina Politi, PhD; Susan M. Kaech, PhD; | Cellular Therapies | Immune suppression; Myeloid cells; NK/NK T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor evasion; Tumor microenvironment |
O7 | P-BCMA-ALLO1 — a Nonviral, Allogeneic Anti-BCMA CAR-T Therapy with Potent Antitumor Function for the Treatment of Multiple Myeloma | Maximilian Richter, PhD; Stacey Cranert, PhD; Yening Tan, MS; Min Tong, MS; Christine Domingo, BS; Elvira Argus, PhD; Samad A. Ibitokou, PhD; Jenessa B. Smith, PhD; Christopher E. Martin, PhD; Xinxin Wang, PhD; Burton E. Barnett, PhD; Eric M. Ostertag, MD, PhD; Julia Coronella, PhD; Devon J. Shedlock, PhD; | Cellular Therapies | Adoptive immunotherapy; CAR T cells |
O8 | The Thrombospondin-1/CD47 signaling axis serve as potential markers of immune checkpoint blockade response modulating immune cell bioenergetics in the tumor microenvironment. | Elizabeth R. Stirling, MS; Adam Wilson; Mitra Kooshki; Lilya Yamaleyeva; Guanxu Jin; Wei Zhang; Lance D. Miller, MS, PhD; Pierre L. Triozzi, MD; David R. Soto-Pantoja, PhD; | Cellular Therapies | Biomarkers; Checkpoint blockade; Metabolism; Tumor microenvironment |
O9 | Enhancing affinity of CD22-directed CAR T cells increases activation signaling and in vivo response to CD22lo leukemia | Zachary H. Walsh, BA; Mark Kohler, MD, PhD; Terry J. Fry, MD; Zachary H. Walsh, BA; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; Leukemia/Lymphoma; Pediatric tumors; T cell; Targeted therapy; Tumor evasion |
O10 | Licensing of CAR-T cell persistence and function by STING agonist in breast cancer | Nuo Xu, PHD candidate; Jonathan S. Serody, MD; Nuo Xu, PHD candidate; Nicholas P. Restifo, MD; Douglas C. Palmer; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; Solid tumors; T cell; Targeted therapy; Tumor microenvironment |
P145 | Expanding Iovance’s tumor infiltrating lymphocytes (TIL) from core biopsies for adoptive T cell therapy using a 22-day manufacturing process | Michelle R. Abelson, PhD; Kenneth D'Arigo; Florangel Hilton; Maria Fardis, PhD, MBA; Cecile Chartier; Cecile Chartier | Cellular Therapies | Adoptive immunotherapy; Immune monitoring; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs) |
P146 | AUTO6NG: Next generation GD2-targeting CAR T-cell therapy with improved persistence and insensitivity to TGFb and checkpoint inhibition for relapsed/refractory neuroblastoma | Daniela Achkova, PhD; Adrian Zarzoso; Yusuf Demir; Fernando J. Gallardo; Maria Stavrou; Marco Della Peruta; Saket Srivastava; Mathew Robson; Shimobi Onuoha; Simon Thomas; Shaun Cordoba; Martin Pule; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; Checkpoint blockade; Cytokine; Solid tumors |
P147 | Effect of chemotherapy on cellular kinetics of NKG2D-based CAR T-cells in metastatic colorectal cancer patients. | Erik Marcelo Alcantar Orozco; Eytan Breman, MSc; Marie-Sophie Dheur, PhD; Fabian Borghese, PhD; Emilie Cerf, PhD; Nathalie Braun; Caroline Lonez, PhD; Anne Flament; Frederic Lehmann, MD; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; Chemotherapy; Clinical trial; Immune monitoring; Solid tumors; T cell |
P148 | High affinity NK cells expressing a PD-L1 chimeric antigen receptor demonstrate anti-tumor activity in head and neck cancer through multiple distinct mechanisms | Yevtte Robbins; Jay Friedman, PhD; Sarah Greene; Kellsye Fabian, PhD; Michelle Padget; John Lee, MD; Patrick Soon-Shiong, MD; Kayvan Niazi; Lennie Sender; Laurent Boissel; Jeffrey Schlom, PhD; James W. Hodge, PhD, MBA; Clint T. Allen, MD; | Cellular Therapies | MDSC; NK/NK T cell; Tumor microenvironment |
P149 | Silencing PD-1 using self-delivering RNAi PH-762- to improve Iovance TIL effector function using Gen 2 manufacturing method | Inbar Azoulay-Alfaguter, PhD; Michelle R. Abelson, PhD; Krit Ritthipichai, DVM, PhD; Kenneth D’Arigo; Florangel Hilton; Marcus Machin, BS; Dingxue Yan; James Cardia; Maria Fardis, PhD, MBA; Cecile Chartier; | Cellular Therapies | Adoptive immunotherapy; Gene expression; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs) |
P150 | 1st-in-human CAR T clinical trial for metastatic breast cancers | Cynthia C. Bamdad, PhD; Andrew K. Stewart, PhD; Pengyu Huang, PhD; Benoit J. Smagghe, PhD; Scott T. Moe, PhD; Tyler E. Swanson; Thomas G. Jeon; Danica M. Page; Ketan M. Mathavan, PhD; Trevor J. Grant, PhD; Rachel M. Herrup; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; Solid tumors; T cell; Targeted therapy; Tumor antigens |
P151 | Solid tumor cytotoxicity by natural killer cells expressing a HER2-directed chimeric antigen receptor enhanced by MyD88/CD40 (MC) | Xiaomei Wang, PhD; Daniel E. Jasinski, PhD; Jan L. Medina; David M. Spencer, PhD; Aaron E. Foster, PhD; Joseph H. Bayle, PhD; | Cellular Therapies | Adoptive immunotherapy; NK/NK T cell; Solid tumors; Targeted therapy |
P152 | Antigen delivery to PBMCs by microfluidic squeezing primes anti-tumor immunity | Matthew G. Booty, PhD; Kelan A. Hlavaty; Emrah I. Ozay, PhD; Carolyne Smith, PhD; Katherine Seidl, PhD; Howard Bernstein, MD, PhD; Armon Sharei; Scott M. Loughhead; | Cellular Therapies | Adoptive immunotherapy; Antigen presenting cells; T cell; Tumor antigens; Vaccine |
P153 | Memory CD8+ T cells are more resistant to cancer stem cell (CSC) suppression than effector CD8+ T cells and are more effective at targeting CSC in a murine melanoma model | Brooke C. Bredbeck, MD; Shibin Qu; Alicia A. Kevelin; Ashley A. Pepple; amy E. Felsted; Anutosh Ganguly; Clifford S. Cho, MD, FACS; Brooke C. Bredbeck; | Cellular Therapies | Adoptive immunotherapy; Immune suppression; Stem cell/cancer-initiating cell; Solid tumors; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs) |
P154 | Development of an Antigen-Presenting Bead Kit for Activation and Expansion of Human Antigen-Specific T Cells | Yelena Bronevetsky, PhD; | Cellular Therapies | Adoptive immunotherapy; Antigen presenting cells; CAR T cells; Cytokine; Immune monitoring; T cell; T cell lineages; Tumor antigens |
P155 | Prospective Translational Study Evaluating Vaccine-Enhanced Adoptive T cell Therapy for Treatment of Osteosarcoma in Companion Dogs | Tammie A. Wahaus, BSBA; Noe Reyes, DVM; Jeffrey N. Bryan, DVM, MS, PhD, DACVIM-Oncology; Jeffrey N. Bryan, DVM, MS, PhD, DACVIM-Oncology; Gary W. Wood, PhD; Brian K. Flesner, DVM, MS, DACVIM-Oncology; Debbie Tate, RVT, VTS (Oncology); Lindsay L. Donnelly, DVM, MS, DACVIM-Oncology; | Cellular Therapies | Adoptive immunotherapy; Neoantigens; Solid tumors; T cell; Tumor antigens; Vaccine |
P156 | Lung cancer sub-types exhibit differential susceptibility to natural killer cell cytotoxicity | Jason G. Cahoon, BS; Shilan Dong, MS; Rafet N. Amoor; Donna L. Sonntag, M.S.; Alexander F. Spurrell; Rachit Ohri, PhD; | Cellular Therapies | Biomarkers; Chemokine; Cytokine; Immune toxicity; NK/NK T cell; Solid tumors; Targeted therapy; Tumor antigens; Tumor microenvironment |
P157 | Optimized process for manufacturing Deep-Primed™ T cells creates product with improved functional characteristics and reactivity against multiple tumor-associated antigens | Shawn P. Carey, PhD; Christine M. McInnis, PhD; Alicia Worthylake; Angela Forte; Elisabeth Brown; Darren Smith; Kate Sackton, PhD; Rosemary Soucy; Tap Maniar, MD; Karsten Sauer, PhD; Thomas L. Andresen, PhD; Andy Rakestraw, PhD; | Cellular Therapies | Adoptive immunotherapy; Cytokine; Solid tumors; T cell; T cell lineages; Targeted therapy; Tumor antigens |
P158 | Suboptimal ER stress Induced Autophagy Regulates Anti-Tumor T Cell Response | Shilpak Chatterjee; Danh T. Tran; Kim Dosung; Satish N. Nadig; Carl Atkinson; Hongjun Wang; J. Alan Dieh; Shikhar Mehrotra, PhD; Paramita Chakraborty, PhD; | Cellular Therapies | Adoptive immunotherapy; Metabolism; T cell; Tumor infiltrating lymphocytes (TILs) |
P159 | TCR fingerprinting and off-target peptide identification | Armen Karapetyan; Chawaree Chaipan; Katharina Winkelbach; Sandra Wimberger; Jun Seop Jeong; Bishnu Joshi; Robert N. Stein, MD PhD; Dennis Underwood, PhD; Eleni Chantzoura, PhD; Alvaro Yague; Jan Bergmann; John C. Castle, PhD; Marc A. Van Dijk, PhD; Marc A. Van Dijk, PhD; Volker Seibert; | Cellular Therapies | Bioinformatics; Immune toxicity; Neoantigens; T cell |
P160 | Engineered natural killer cells redirected against adenosinergic immunometabolic suppression for the immunotherapy of lung carcinoma | Andrea Chambers, MS; Kyle B. Lupo, BS; Jiao Wang, PhD; Sandro Matosevic, PhD; | Cellular Therapies | Adoptive immunotherapy; Cytokine; Gene expression; Metabolism; NK/NK T cell; Solid tumors; Targeted therapy; Tumor microenvironment |
P161 | High-efficiency CAR-T cell manufacturing by improved scalable electroporation | Jian Chen, PhD; George Sun; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; Gene expression; NK/NK T cell; T cell |
P162 | Development of CD4+ and CD8+ TCRαβ-deficient bioluminescent reporter T cells for screening and characterization of neoantigen-specific TCRs | Zhijie J. cheng, PhD; Jamison J. Grailer, PhD; Michael Slater; Pete Stecha; Jim Hartnett; Frank Fan, PhD; Mei Cong, PhD; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; Neoantigens; T cell; Targeted therapy |
P163 | Effect of common gamma-chain cytokines on myeloid-derived suppressor cell and M2 macrophage suppressive function: Implications for cellular immunotherapy | Anna Cole, BA; Charlotte Rivas; Josue Pineda; Corrine Baumgartner; Stephanie Fetzko; Robin Parihar; | Cellular Therapies | CAR T cells; Cytokine; Immune suppression; Monocyte/Macrophage; Myeloid cells; MDSC; Solid tumors; Tumor microenvironment |
P164 | Effect of NK cell treatment on PD-L1 expression and anti-PD-L1 response | Alicja Copik, PhD; Jeremiah L. Oyer; Sarah B. Gitto; Deborah A. Altomare, PhD; | Cellular Therapies | Adoptive immunotherapy; Checkpoint blockade; NK/NK T cell; Solid tumors |
P165 | Robust, reproducible and highly scalable manufacturing of P-BCMA-ALLO1, an allogeneic CAR-T stem cell memory product for Multiple Myeloma, from numerous healthy donors | Stacey Cranert, PhD; Maximilian Richter, PhD; Min Tong, MS; Leslie Weiss, M.S.; Yening Tan, MS; Eric Ostertag, MD/PhD; Julia Coronella, PhD; Devon Shedlock, PhD; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; T cell; Targeted therapy |
P166 | ET140202 T-cell therapy for the treatment of liver cancer is built upon a novel antibody-T cell receptor (AbTCR) ARTEMIS™ T-cell platform | Jun Cui, PhD; Pengbo Zhang; Hongruo Yun; Yiyang Xu; Lucas Horan, PhD; Shaohua Xu; Sean Xu; Hong Liu; | Cellular Therapies | CAR T cells; Solid tumors; T cell |
P167 | Improved efficacy leveraging CAR-T therapeutics that produce tightly controlled, tumor proximal, immunomodulatory outputs | Michon Pinnix; Krista McNally; Jay Danao, BS; Melissa Fardy; Rachel Hovde, MS; Charlotte Davis; Nicole Grant; Dianna Lester-Zeiner; David Mai; Ben Wang, PhD; Gus Zeiner, PhD; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; Cytokine; Gene expression; Immune suppression; Solid tumors; T cell; Tumor microenvironment |
P168 | Role and Function of T-cell immunoglobulin– and mucin domain–containing (TIM)–3 Receptor on Natural Killer Cells in Solid Tumors | Tram N. Dao; Sandro Matosevic, PhD; | Cellular Therapies | Immune suppression; NK/NK T cell; Solid tumors |
P169 | Enriching non-genetically modified antigen specific marrow infiltrating lymphocytes (MILs) to target HPV+ oropharyngeal squamous cell carcinoma | Danielle W. Dillard, PhD Candidate; Vanessa Chan; LAKSHMI RUDRARAJU, MS; Elizabeth DeOliveira; Amy Thomas; Ervin Griffin; Megan K. Heimann, PhD candidate; Luca Biavati, MD; Elizabeth Zawidzka; Marguerrita El Asmar; Drew M. Pardoll, MD, PhD; Kellie N. Smith, PhD; Carole Fakhry, MD; Ivan M. Borrello, MD; | Cellular Therapies | Adoptive immunotherapy; Antigen presenting cells; Bioinformatics; Solid tumors; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor antigens |
P170 | Sequential anti-CD19, anti-CD22, and anti-CD20 autologous chimeric antigen receptor T cell (CAR-T) therapies treating a child with relapsed refractory Burkitt lymphoma | Juan Du, MD; Yonghong Zhang, Professor; | Cellular Therapies | B cell; CAR T cells; Leukemia/Lymphoma; Pediatric tumors |
P171 | T cell receptor gene therapy for a public neoantigen derived from mutated PIK3CA, a dominant driver oncogene in breast and endometrial cancers | Smita S. Chandran, PhD; Jiaqi Ma; Martin Klatt, PhD; Friederike Dundar, PhD; Paul Zumbo; Matthew R. Femia; Doron Betel, PhD; David Scheinberg; Brian M. Baker, PhD; Christopher A. Klebanoff, MD; Smita S. Chandran, PhD; | Cellular Therapies | Adoptive immunotherapy; Gene expression; Neoantigens; Proteomics; T cell |
P172 | Shape and Material Properties Increase Artificial Antigen Presenting Cell Effectiveness | Savannah Est Witte, BS; Kaitlyn G. Calebrisi; Jordan J. Green, PhD; Savannah Est Witte, BS; | Cellular Therapies | Adoptive immunotherapy; Antigen presenting cells; T cell; Targeted therapy |
P173 | Case reports: Correlates of response following adoptive transfer of ADP-A2M4, affinity-enhanced T-cells targeting MAGE-A4, in synovial sarcoma | Svetlana Fayngerts, PhD; Zohar Wolchinsky; Shravani Shitole; Joana Senra; Rebecca Dryer-Minnerly, PhD; Ruoxi Wang; Jean-Marc Navenot, PhD; Olga Ochkur; Gareth Betts, PhD; Natalie Bath, MSc; Erin Van Winkle; Tom Holdich; Malini Iyengar, PhD; Rafael Amado, MD; Marcus O. Butler, MD; David S. Hong, MD; Alex J. Tipping, PhD; Samik Basu, MD; Indu Ramachandran, PhD | Cellular Therapies | Adoptive immunotherapy; Clinical study; Cytokine; Solid tumors; T cell; Targeted therapy; Tumor antigens; Tumor microenvironment |
P174 | Combinatorial tumor targeting using a novel switchable RevCAR system | Anja Feldmann, PhD; Anja Hoffmann; Ralf Bergmann; Liliana Loureiro, PhD; Enrico Kittel-Boselli; Nicola Mitwasi; Stefanie Koristka; Justyna Jureczek; Nicole Berndt; Claudia Arndt; Michael Bachmann; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; Targeted therapy |
P175 | PD-L1: A side-effect of T cell engagement or a main player in MDS tumor immune evasion? | Valentina Ferrari, BA; Alison Tarke; Hannah Fields; Tiffany Tanaka; Rafael Bejar; Thomas A. Lane, MD; Antonella Vitiello, PhD; Maurizio Zanetti, MD; | Cellular Therapies | Adoptive immunotherapy; Myeloid cells; Neoantigens; T cell; Tumor evasion; Tumor microenvironment |
P176 | Adoptive cell therapy using tumor-infiltrating lymphocytes (TIL) for metastatic uveal melanoma: feasibility of treatment using a product generated from the primary tumor | Marie-Andree Forget, PhD; Cara Haymaker, PhD; Orenthial J. Fulbright, BS; Shawne Thorsen, BS; Esteban Flores, BS; Arely Wahl, MSc; Rene J. Tavera, BS; Benjamin Tintera, BS; Timothy L. Woody; Michelle Williams; Yun Shin Chun; Patrick Hwu, MD; Dan S. Gombos; Sapna Patel, MD; Rodabe N. Amaria, MD; Chantale Bernatchez; | Cellular Therapies | Adoptive immunotherapy; Clinical study; Clinical trial; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs) |
P177 | NF-kB p50-deficient immature myeloid cell (p50-IMC) adoptive transfer slows the growth of murine prostate and pancreatic ductal carcinoma | Rahul Suresh, PhD; David Barakat, PhD; Theresa Barberi, PhD; Lei Zheng, PhD MD; Elizabeth M. Jaffee, MD; Kenneth J. Pienta, MD; Alan D. Friedman, MD; | Cellular Therapies | Adoptive immunotherapy; Dendritic cell; Monocyte/Macrophage; Myeloid cells; Tumor microenvironment |
P178 | Dual inhibition of PI3Kdelta and PI3Kgamma to enhance mitochondrial mass and ex vivo expansion of central and stem cell memory T cells from CLL patients | Christopher R. Funk, BS; Shuhua Wang, MD; Alexandra Waller, BS; Lauren C. Fleischer, BS; Aditi Sharma; Harold T. Spencer, PhD; Vikas Gupta, MD, PhD; Sruthi Ravindranathan, PhD; Mala Shanmugam, PhD; Christopher Flowers, MD, MS; Edmund K. Waller, MD, PhD, FACP; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; Costimulation; Leukemia/Lymphoma; T cell |
P179 | Checkpoint Cbl-b siRNA-based APN401 adoptive cell therapy: Superior efficacy & immune memory induction in murine hepatocellular carcinoma following APN401 monotherapy and synergism with anti-PD1. | Anderson Gaweco, MD, PhD; Anderson Gaweco, MD, PhD; Kathrin Thell; Maria Urban; Julia Harrauer; Isabella Haslinger; Josef Penninger; Vincent Chung; Anthony El-Khoueiry, MD; Carlos Becerra, MD; | Cellular Therapies | Adoptive immunotherapy; Checkpoint blockade; Coinhibition; NK/NK T cell; Solid tumors; T cell; Targeted therapy |
P180 | SENTI-101, an allogeneic cell product, induces potent and durable anti-tumor immunity in pre-clinical models of peritoneal carcinomatosis | Alba Gonzalez Junca, PhD; Gary Lee, PhD; Alba Gonzalez Junca, PhD; Archana Nagaraja, PhD; Alyssa Mullenix; Russell M. Gordley, PhD; Daniel O. Frimannson, PhD; Anissa Benabbas; Chen-Ting Lee, PhD; Tiffany A. Truong; Mengxi Tian; Allison Bi. Quach; Rishi Savur; Rowena Martinez; Alyssa Perry-McNamara; Don-Hong Wang, PhD; Ori Maller, PhD; Dharini Iyer, PhD; Ashita Magal; Christina J. Huynh; Carmina C. Blanco; Jack T. Lin, PhD; Brian S. Garrison, PhD; Philip Lee, PhD; Sravani Mangalampalli; Timothy K. Lu, MD, PhD; | Cellular Therapies | Adoptive immunotherapy; Cytokine; Solid tumors; Tumor microenvironment |
P181 | Multi-phenotype CRISPR-Cas9 screens identify p38 kinase as a target for adoptive immunotherapies | Devikala Gurusamy, PhD; Suman Vodnala; Amanda Henning; Rigel Kishton; Tori N. Yamamoto; Arash Eidizadeh; Li Jia; Christine M. Kariya; Mary Black; Robert L. Eil; Douglas Palmer; Zhiya Yu; Jenny Pan, MD; Madhusudhanan Sukumar; Shashank J. Patel; Nicholas P. Restifo, MD; | Cellular Therapies | Adoptive immunotherapy; Bioinformatics; CAR T cells; Leukemia/Lymphoma; Metabolism; Solid tumors; T cell; T cell lineages; Tumor infiltrating lymphocytes (TILs); Tumor antigens |
P182 | GAIA-102: a new class NK cell-like phenotype manufactured in accordance with GMP/GCTP that can eliminate solid tumors | Yui Harada, PhD; Yoshikazu Yonemitsu, MD, PhD; | Cellular Therapies | Adoptive immunotherapy; MDSC; NK/NK T cell; Solid tumors |
P183 | Development of novel chimeric antigen receptor T cells for immunotherapy of hepatocellular carcinoma | Yukai He, PhD; Leidy Caraballo Galva; Xiaotao Jiang; | Cellular Therapies | Adoptive immunotherapy; Antibody |
P184 | Activating marrow infiltrating lymphocytes in hypoxia enhances their efficacy in adoptive T-cell therapy | Megan K. Heimann, PhD candidate; Ervin Griffin; Luca Biavati, MD; Amy Thomas; Danielle Dillard; Elizabeth Zawidzka; Brianna Richardson; Robert D. Leone; Gregory Szeto; Kimberly A. Noonan, PhD; Ivan M. Borrello, MD; | Cellular Therapies | Adoptive immunotherapy; Cytokine; Gene expression; Metabolism; T cell; Tumor antigens; Tumor microenvironment |
P185 | T cell antigen presenting cell (tAPC) is a strategy to induce CAR T expansion in vivo in the absence of a tumor for on-target toxicity studies | Yen Ho, BS; Jon Jones, BA; Jon Jones, BA; Patrick Carlson, BS; Patrick Carlson, BS; Cyr de Imus; Rebekah Turk; Dina Alcorn; Kyle Kolaja; Ruth Salmon, PhD; Thomas Long; | Cellular Therapies | Adoptive immunotherapy; Antigen presenting cells; CAR T cells; Immune toxicity; T cell |
P186 | Evaluation of antigen-specific T-cell immunity at the single cell level using large panels of DNA barcoded MHC multimers | Kivin KJ. Jacobsen, PhD; Dagmar Walter; Michael Stubbington; Katherine Pfeiffer; Charlotte Halgreen; Liselotte Brix, phd; Stephane Boutet; Kivin KJ. Jacobsen, PhD; | Cellular Therapies | Adoptive immunotherapy; Biomarkers; Gene expression; Immune monitoring; Neoantigens; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor antigens |
P187 | Single-cell RNA sequencing and functional assessment of healthy donor- and cancer patient-derived T and CAR-T cells | Zinkal Padalia, MS; Konstantinos Karagiannis, PhD; Brigid Mcewan, MA; Vahan Simonyan, PhD; Jonathan Terrett, PhD; Demetrios Kalaitzidis, PhD; Demetrios Kalaitzidis, PhD; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; Leukemia/Lymphoma; Systems biology; T cell; Targeted therapy; Tumor antigens |
P188 | Enhanced anti-tumor activity of human placental CD34+ derived natural killer cells in combination with ACY-241 for multiple myeloma immunotherapy | Lin Kang, PhD; Xiaokui Zhang; Shuyang He; Vanessa Voskinarian-Berse; Bhavani Stout; Valentina Rousseva; William van der Touw; James Edinger; Robert Hariri; | Cellular Therapies | Adoptive immunotherapy; Chemotherapy; NK/NK T cell |
P189 | Tumor Treating Fields (TTFields) induce immunogenic cell death resulting in enhanced antitumor efficacy when combined with anti-PD-1 therapy | Noa Kaynan, PhD; Tali Voloshin; Shiri Davidi; Yaara Porat; Anna Shteingauz; Mijal Munster; Rosa S. Schnaiderman; Catherine Tempel Brami; Yaniv Alon; Einav Zeevi; Karnit Gotlib; Roni Blat; Orni Tal Yitzhaki; Shay Cahal; Aviran Itzhaki; Eilon D. Kirson; Uri Weinberg, MD PhD; Adrian Kinzel; Yoram Palti; Noa Kaynan, PhD; Moshe Giladi; | Cellular Therapies | Checkpoint blockade; Dendritic cell; Immune adjuvant; Solid tumors |
P190 | Single-day CAR manufacturing platform using mRNA and Flow Electroporation Technology | Michael Kuo; Robert Keefe, PhD; Linhong Li, PhD; Angelia Viley; Mary Loveras; Brian Mulhern; Melanie Hartsough; Robert Keefe, PhD; Claudio A. Dansky Ullmann, MD; Dhana Chinnasamy; | Cellular Therapies | CAR T cells; Clinical study; Clinical trial; Solid tumors; T cell; Targeted therapy |
P192 | Anti-HLA-G Antigen Receptor T-Cells Exhibit Potent Anti-Tumor Effects Against Human Solid Tumors | Alan L. Epstein, MD, PhD; Aida Kouhi, PhD candidate; | Cellular Therapies | CAR T cells; Neoantigens; Solid tumors; T cell; Targeted therapy; Tumor antigens |
P193 | CoStAR (Costimulatory Antigen Receptor) Enhancement of Tumour Infiltrating Lymphocyte Therapy | Gray Kueberuwa, PhD; John S. Bridgeman, PhD; Martina Sykorova; milena Kalaitsidou; Michelle L. Le Brocq; Martina Sykorova; Robert Hawkins; | Cellular Therapies | Adoptive immunotherapy; Costimulation; Immune contexture; T cell; Tumor infiltrating lymphocytes (TILs) |
P194 | Use of stimulatory cells in conjunction with IL-12 and IL-18 augments NK cell expansion and transduction, drives a memory phenotype, and improves in vitro and in vivo CAR NK activity | Anmol Vohra, MS; Katherine Jamboretz, MS; Sasha Lazetic; Denise Gonzalez; Daofeng Liu, PhD; Ivan Chan, PhD; James B. Trager, PhD; | Cellular Therapies | Cytokine; NK/NK T cell |
P195 | Loss of function of the TSC1-TSC2 complex renders tumors eligible for GD3 CART therapy | Ancy Thomas; Saurav Sumughan; Zhussipbek Mukhatayev; Emilia Dellacecca; Nicola Lancki; Levi Barse; Jesus Zamora-Pineda; Suhail Akhtar; Maria Picken; Denise Scholtens; Daniel Dilling; Richard P. Junghans, PhD, MD; Caroline Le Poole; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; NK/NK T cell; Solid tumors; T cell; Tumor antigens |
P196 | The first step toward the universal cell therapy: Simultaneous removal of HLAs (Human leukocyte antigens) using CRISPR-mediated quadruple genome editing in allogeneic T cells | Jeewon Lee, Ph D; Munkyung Kim; Joong Hyuk Sheen; Jihye Ryu; Yu Young Kim; Okjae Lim; | Cellular Therapies | Adoptive immunotherapy; Gene expression; T cell |
P197 | The development of an autologous neoantigen specific T cell product from peripheral blood, NEO-PTC-01, through the ex-vivo induction protocol, NEO-STIM™ | Divya R. Lenkala; Marit M. Van Buuren, PhD; Brian McCarthy; Jessica Kohler, PhD; Michael Nelson; Flavian Brown; Yvonne Ware, Masters; Yuting Huang, Master of Science; Janani Sridar; Yusuf S. Nasrullah, Master's in Biological Research, United Kingdom; Dewi Harjanto; Joost H. Van Den Berg, PharmD; Matthew Goldstein, MD, PhD; Richard B. Gaynor, MD; | Cellular Therapies | Adoptive immunotherapy; Antigen presenting cells; Bioinformatics; Immune monitoring; Neoantigens; T cell |
P198 | Short-lived and extended half-life target modules for redirecting UniCAR T-cells against sialyl-Tn expressing cancer cells | Liliana Loureiro, PhD; Liliana Loureiro, PhD; Anja Feldmann, PhD; Ralf Bergmann; Stefanie Koristka; Nicole Berndt; Nikolett Hegedüs; Domokos Máthé; Paula Videira; Michael Bachmann; Claudia Arndt; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; Solid tumors; Targeted therapy |
P199 | Generation of functionally and phenotypically mature, allogeneic natural killer cells from human induced pluripotent stem cells under chemically-defined, feeder- and serum- free culture conditions | Kyle B. Lupo, BS; Andrea Chambers, MS; Sandro Matosevic, PhD; | Cellular Therapies | Adoptive immunotherapy; NK/NK T cell; Stem cell/cancer-initiating cell; Solid tumors |
P200 | CART-engineered Marrow-infiltrating Lymphocytes (MILsTM) are more polyfunctional than their matched peripheral blood counterparts | Eric R. Lutz, PhD; LAKSHMI RUDRARAJU, MS; Elizabeth DeOliveira; Srikanta Jana; Jing Zhou, MD, PhD; Sean G. Mackay, MBA; Ivan M. Borrello, MD; Kimberly A. Noonan, PhD; Eric R. Lutz, PhD; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; T cell |
P201 | Comparison of phenotype and anti-tumor profile of CD19-CAR-T cells generated from either umbilical cord blood- or peripheral blood-derived T lymphocytes | Cristina Maccalli, PhD; Dhanya Kizhakayil, PhD; Shilpa Ravindran, BSc.; Saad Rasool; Rebecca Mathew; Valentina Mattei; Monica Casucci, PhD; Sara Deola, MD, PhD; Chiara Cugno, MD; Damien Chaussabel; Sara Tomei, PhD; Christof von Kalle; Cristina Maccalli, PhD; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; Cytokine; Gene expression; Immune monitoring; Leukemia/Lymphoma; Systems biology; T cell; Tumor antigens |
P202 | Mechanisms underlying human placental CD34+-derived natural killer cell cytotoxicity against glioblastoma | Tanel Mahlakoiv, PhD; Bhavani Stout; Valentina Rousseva; Irene Raitman; Lin Kang, PhD; Robert Hariri; Xiaokui Zhang; William van der Touw; Tanel Mahlakõiv; | Cellular Therapies | Adoptive immunotherapy; Gene expression; NK/NK T cell; Solid tumors |
P203 | Discovery and characterization of the first fully human Phosphopeptide Tumor Target-specific T cell receptor | Xavier Michelet, PhD; Eleni Chantzoura, PhD; Ekaterina Breous-Nystrom, PhD; Alessandra Franchino; Rachel Smith; Daniel Pollacksmith; Jan Bergmann; Alvaro Sebastian Yague; Paisley T. Myers, PhD; Erin Jeffrey; Benjamin Wolf; Dennis Underwood, PhD; Marc A. Van Dijk, PhD; Arthur A. Hurwitz, PhD; | Cellular Therapies | Adoptive immunotherapy; Leukemia/Lymphoma; Neoantigens; T cell; Targeted therapy; Tumor antigens |
P204 | Ex vivo-activated allogeneic CD4+ T-cells disrupt immunosuppressive tumor microenvironment, and induce host tumor-specific cytotoxic T-cells in mice | Kazuhiro Mochizuki, MD, PhD; Shogo Kobayashi; Nobuhisa Takahashi; Hideki Sano; Yoshihiro Ohara; Shin Mineishi, MD; Yi Zhang; Atsushi Kikuta; | Cellular Therapies | Adoptive immunotherapy; Antigen presenting cells; Dendritic cell; Inflammation; Monocyte/Macrophage; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
P205 | Automated, Closed Bioreactors for T Cell Processing and Dendritic Cell-T Cell Co-Culture | Lekhana Bhandary, BS, PhD; Andrew Kozbial, BS, PhD; Shashi Murthy, BS, PhD; Shashi Murthy, BS, PhD; | Cellular Therapies | CAR T cells; Dendritic cell; Monocyte/Macrophage; Neoantigens; T cell |
P206 | Transmembrane and linker domain amino acid composition alters chimeric antigen receptor (CAR) membrane residence and may conceal detection of novel functional CAR formats | Dina Schneider, PhD; Virginia Hoglund, MS; Ying Xiong, PhD; Darong Wu, MS; Boro Dropulic, PhD, MBA; Rimas J. Orentas, PhD; Rimas J. Orentas, PhD; Rimas J. Orentas, PhD; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; T cell |
P207 | A patient-driven ex vivo 3D tumor organoid model to assess efficacy of tumor infiltrating T-cell adoptive cell therapy | Jenny Kreahling, PhD; Mibel Pabon, PhD; Mibel Pabon, PhD; Melba Page, PhD; Vijayendra Agrawal, PhD; Soner Altiok, MD, PhD; | Cellular Therapies | Adoptive immunotherapy; Biomarkers; Immune monitoring; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma |
P208 | Impact of combined blockade of PD1 and activation of CD137 on tumor infiltration and tumor cell killing efficacy of TILs in an ex vivo autologous 3D tumoroid model of NSCLC patient samples. | Jenny Kreahling, PhD; Melba Page, PhD; Melba Page, PhD; Mibel Pabon, PhD; Vijayendra Agrawal, PhD; Soner Altiok, MD, PhD; | Cellular Therapies | Adoptive immunotherapy; Antibody; Checkpoint blockade; Cytokine; Immune monitoring; Solid tumors; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
P209 | Hijacking CAR-CD19 T cells to potently control Her2-positive solid tumors in vitro and in vivo through the use of unique and selective bridging proteins | Paul Rennert, PhD; Christine Ambrose, PhD; Fay Dufort, PhD; Lihe Dufort; Alyssa Birt; Thomas Sanford; Lan Wu; Roy Lobb, PhD; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; Solid tumors; Tumor antigens; Tumor evasion |
P210 | Deep phenotypic and functional analysis of transduced anti-CD19 CAR T cells and untransduced T cells in patients treated with axi-cel by single cell mass cytometry | Yohei Arihara, MD, PhD; Caron Jacobson, MD; Philippe Armand, MD; John M. Rossi, MS; Nathalie Scholler, MD, PhD; Stuart Sievers, PhD; Edmund Chang, PhD; Mauro Avanzi, MD, PhD; Adrian Bot, MD, PhD; Jerome Ritz, MD; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; Clinical study; Immune monitoring; Leukemia/Lymphoma |
P211 | Combining Deep™ IL-12 Primed and Deep™ IL-15 Primed T cells leverages complementary mechanisms to enhance anti-tumor activity | Katharine Sackton, PhD; Elena Geretti, PhD; Pengpeng Cao, PhD; Shawn P. Carey, PhD; Xiaoyan Liang; Jonathan Nardozzi, PhD; Zishu Gui; Alicia Worthylake; Glenn Leary; Becker Hewes, MD; Tap Maniar, MD; Jonathan B. Fitzgerald, PhD; Andy Rakestraw, PhD; Karsten Sauer, PhD; Douglas Jones, PhD; Thomas L. Andresen, PhD; | Cellular Therapies | Adoptive immunotherapy; Cytokine; Solid tumors; T cell |
P212 | Potential clinical application of tumor-infiltrating lymphocyte therapy for ovarian epithelial cancer prior or post-resistance to chemotherapy | Donastas Sakellariou-Thompson, BS; Marie-Andree Forget, PhD; Emily Hinchcliff, MD; Joseph Celestino; Patrick Hwu, MD; Amir A. Jazaeri, MD; Cara Haymaker, PhD; Chantale Bernatchez; | Cellular Therapies | Adoptive immunotherapy; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs) |
P213 | Conversion of peripheral blood mononuclear cells into tumor-specific cytolytic cell populations using tumor cells engineered with multiple immunomodulatory factors | Joshua Keegan; James Lederer; Frank Borriello, MD, PhD; Nathan Schomer, MS; James Lederer; | Cellular Therapies | Adoptive immunotherapy; Antigen presenting cells; Costimulation; Cytokine; Immune adjuvant; NK/NK T cell; T cell; T cell lineages; Targeted therapy; Vaccine |
P214 | T cells precision engineered to express neoepitope-specific TCRs cloned from a patient with colorectal cancer specifically target and kill relevant neoantigen-expressing tumor cells | Barbara Sennino, PhD; Adam Litterman; John Gagnon; Andrew Conroy; Bhamini Purandare; Zheng Pan, PhD; Dalmas Olivier; Kyle Jacoby, PhD; Songming Peng, PhD; Alex Franzusoff, PhD; Stefanie J. Mandl, PhD; | Cellular Therapies | Adoptive immunotherapy; Neoantigens |
P215 | Depletion of CD45RA-positive cells potentiates the reactivation of EBV-specific T-cells from EBV positive lymphoma patients | Sandhya Sharma, BSc.; Sandhya Sharma, BSc.; Naren Mehta; Kathan Parikh, RA; Cliona M. Rooney, PhD; | Cellular Therapies | Adoptive immunotherapy; Antigen presenting cells; T cell; Tumor antigens |
P217 | An NK cell line (PD-L1 t-haNK) engineered to target PD-L1 efficiently kills tumor cells and myeloid derived suppressor cells | Kellsye Fabian, PhD; Michelle Padget; Renee N. Donahue, PhD; kristen solocinski, PhD; Clint T. Allen, MD; John Lee, MD; Patrick Soon-Shiong, MD; Jeffrey Schlom, PhD; James W. Hodge, PhD, MBA; | Cellular Therapies | MDSC; NK/NK T cell; Solid tumors; Targeted therapy |
P218 | A novel, bioluminescent assay for the selective detection of target cell killing in mixed cultures | Richard Somberg, PhD; Brock Binkowski; Aileen Paguio; Peter Stecha; Chris Eggers; Braeden Butler; Michael Beck; Julia Gilden, PhD; Jey Cheng; Mei Cong, PhD; Frank Fan, PhD; | Cellular Therapies | Adoptive immunotherapy; Antibody; CAR T cells; Chemokine; Costimulation; Cytokine; NK/NK T cell; T cell; Targeted therapy |
P220 | Targeting neoantigens with immunotherapy: Are we limited to pre-existing autologous neoantigen-specific T-cells? | Aline Bracher; Slavoljub Milosevic; Daniel Sommermeyer; Daniel Sommermeyer; | Cellular Therapies | Adoptive immunotherapy; Neoantigens; Tumor antigens |
P221 | Superior anti-tumor activity of metabolically enhanced bispecific antibody armed CAR-less Bionic T cells | Archana Thakur, PhD; John Scholler; Edwin T. Bliemeister; Carl H. June, MD; Lawrence G. Lum, MD, DSc; | Cellular Therapies | Adoptive immunotherapy; Antibody; Chemokine; Cytokine; Solid tumors; T cell; Targeted therapy |
P222 | Modulating BRD4 in T cells using self-delivery RNAi to improve adoptive cell therapy of cancer | Jeroen Melief, PhD; Laura L. Van Leeuwe Kirsch, BSc; Esmeralda Hemme; John A. Barrett, PhD; Simon P. Fricker, PhD; Gerrit Dispersyn, PhD; Rolf Kiessling, MD, PhD; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; T cell; Tumor infiltrating lymphocytes (TILs) |
P224 | Case studies of sarcoma and MRCLS following treatment with NY-ESO-1 TCR T Cells (GSK3377794): correlates of predictable response characteristics | Brian Van Tine, MD, PhD; Sandra P. D'Angelo, MD; Alexandra Gyurdieva; Laura Johnson; David C. Turner; Jenna Tress; M. Phillip DeYoung; Yuehui Wu; Aisha N. Hasan, MBBS MD; Dejka Araujo, MD; | Cellular Therapies | Adoptive immunotherapy; Clinical study; Cytokine; T cell |
P225 | Generating iPSC-derived CAR T cells with an endogenous T cell phenotype and conventional CAR T functionality | Zhiqiang (Daniel) Wang, Ph.D; Zhiqiang (Daniel) Wang, Ph.D; Hellen McWilliams-Koeppen, MS; Christian Huynh, BS; Hernan Reza; Vibhuti Vyas; Xiuli Wang, PhD; Wen-Chung Chang, MS; Julie R. Ostberg, PhD; Renate Starr, MS; Jamie Wagner; Brenda Aguilar, BS; Xiwei Wu; Jinhui Wang; Wei Chen; Chris Seet; Gay Crooks; Christine Brown, PhD; Stephen J. Forman, MD; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; Leukemia/Lymphoma; Stem cell/cancer-initiating cell; T cell; T cell lineages |
P226 | Iovance Gen2 TIL manufacturing process produces drug products that exhibit favorable quality attributes for adoptive cell transfer across 5 solid tumor indications | Seth Wardell; Seth Wardell; Maritza Lienlaf-Moreno; Lavakumar Karyampudi; Anand Veerapathran, PhD; Ian Frank; Michelle A. Blaskovich, BS; Kenneth Onimus; Arvind Natarajan; Maria Fardis, PhD, MBA; Joe Wypych | Cellular Therapies | Adoptive immunotherapy; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs) |
P227 | Co-expression of the metabolic enzyme GOT2 with a GPC3-targeted CAR-T overcomes challenges of the solid tumor microenvironment, substantially improving therapeutic efficacy in solid tumor xenografts | Kathleen R. Whiteman, MS; Kathleen R. Whiteman, MS; Tapasya Pai; Eugene Choi; Taylor Hickman; Tyler Johnson; Luke Barron, PhD; Taylor Friedman; Madaline Gilbert; Binzhang Shen; Seth Ettenberg; Kathleen McGinness; Greg Motz; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; Metabolism; Solid tumors; T cell; Tumor microenvironment |
P228 | Tumor infiltrating lymphocyte recognition of shared neoantigens from mutated DNA repair/remodeling proteins in a patient with metastatic pancreatic adenocarcinoma | Ghanshyam Singh S. Yadav, PhD; Chetana Bhaskarla, PhD; Smriti Chaurasia, PhD; Joshua Tobin; Xinming Zhuo; Yinghong Pan; Annerose Berndt; Udai S. Kammula, MD, FACS; | Cellular Therapies | Adoptive immunotherapy; Neoantigens; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs) |
P229 | The Next Generation “off-the-shelf” Universal CAR for Adoptive Immunotherapy | Weichih Yang, PhD; Yun Ji; Xiaobing Luo; Huijuan Cui; Michael Patrick; Yutian Wei; Shigui Zhu; Jiaqi Huang; Xin Yao; Yihong Yao; Aibing Liang; Ping Li; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; T cell; T cell lineages |
P230 | Activating Antigen Carriers for Cancer Therapy: Preclinical Immune Responses Drive Tumor Regression | Defne Yarar, PhD; Amritha Ramakrishnan; Katarina Blagovic, PhD; Katherine Seidl; Howard Bernstein, MD, PhD; Armon Sharei; | Cellular Therapies | Adoptive immunotherapy; Immune adjuvant; Solid tumors; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor antigens; Vaccine |
P231 | Invariant natural killer T cells as an allogeneic cell therapy platform | Burcu Yigit, PhD; Xavier Michelet, PhD; Simon Yue; Darrian Moskowitz; Mark Exley; Burcu Yigit, PhD; | Cellular Therapies | Adoptive immunotherapy; NK/NK T cell |
P232 | Characterization of ADCC Resistance in Multiple Cancer Types | David Zahavi, MS, BS; Yongwei ZHANG; Sandra Jablonski, PhD; Louis M. Weiner, MD; | Cellular Therapies | Antibody; NK/NK T cell; Targeted therapy; Tumor antigens; Tumor evasion |
P233 | RTX-321, an Allogeneic Artificial Antigen Presenting Red Cell Therapeutic, Expressing MHC I-Peptide, 41BBL and IL12, Promotes Antigen-Specific T Cell Expansion and Anti-Tumor Activity in HPV16+ Tumors | Xuqing Zhang, PhD; Tiffany F. Chen; | Cellular Therapies | Antigen presenting cells; Costimulation; Cytokine; T cell; Tumor antigens |
P234 | DAP10 and DAP12 Signaling Based CAR Circumvents Ligand-dependent Tonic Signaling and Mediates Potent Anti-tumor Response In Vivo | Alan L. Epstein, MD, PhD; Long Zheng, PhD Candidate; | Cellular Therapies | CAR T cells; Immune toxicity; Neoantigens; T cell; Targeted therapy; Tumor antigens |